Abstract
Vaccination is currently the best weapon to control the COVID-19 pandemic. However, an alarming number of novel variants termed Variants of Concern (VoC) were found to harbor mutations that diminished the neutralizing capacity of antibodies elicited by the vaccines. We have investigated the neutralizing titers of antibodies from sera of humans and rats immunized with the MVC-COV1901 vaccine against pseudoviruses coated with the wildtype, D614G, B.1.1.7, or B.1.351 spike proteins. Rats vaccinated with two doses of adjuvanted S-2P retained neutralization activities against the B.1.351 variant, albeit with a slight reduction compared to wildtype. Phase 1 vaccinated subjects showed more reduced neutralization abilities against the B.1.351 variant. The study is among the first, to our knowledge, to demonstrate dose-dependent neutralizing responses against VoCs, particularly against B.1.351, from different doses of antigen in a clinical trial for a subunit protein COVID-19 vaccine. The appearance of vaccine escape variants is a growing concern facing many current COVID-19 vaccines and therapeutics. Strategies should be adopted against the ever-changing nature of these variants. The observations of this study grant us valuable insight into preemptive strikes against current and future variants.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT04487210
Funding Statement
No external funding was received.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The protocol has been approved by the 132nd meeting of Research Ethics Committee C of the National Taiwan University Hospital (NTUH) on Aug 3, 2020. The committee is organized under, and operates in accordance with, the Good Clinical Practice guidelines and governmental laws and regulations. Approval by the Ministry of Health and Welfare is mandatory before project implementation. The duration of this approval is six months (Aug 6, 2020 to Feb 5, 2021). The investigator is required to report Serious Adverse Events and Unanticipated Problems in accordance with the governmental laws and regulations and NTUH requirements and apply for a continuing review not less than six weeks prior to the approval expiration date. Chairman of Research Ethics Committee C: Daniel Fu-Chang Tsai, M.D. NTUH-REC No. 202007029MSC Protocol No. CT-COV-11
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The datasets generated during and analyzed during the current study are available from the corresponding author on reasonable request.
